Prominent roles of ribosomal S6 kinase 4 (RSK4) in cancer
- 1 March 2021
- journal article
- review article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 219, 153374
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functionsMolecular Systems Biology, 2013
- Improving the Affinity of SL0101 for RSK Using Structure-Based DesignACS Medicinal Chemistry Letters, 2013
- Analogs of the RSK inhibitor SL0101: Optimization of in vitro biological stabilityBioorganic & Medicinal Chemistry Letters, 2012
- Aberrant Methylation of the X-Linked Ribosomal S6 Kinase RPS6KA6 (RSK4) in Endometrial CancersClinical Cancer Research, 2011
- Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein KinasesMicrobiology and Molecular Biology Reviews, 2011
- The RSK family of kinases: emerging roles in cellular signallingNature Reviews Molecular Cell Biology, 2008
- MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targetsClinical Science, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- A clickable inhibitor reveals context-dependent autoactivation of p90 RSKNature Chemical Biology, 2007
- BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoformsin vitroandin vivoBiochemical Journal, 2006